CIK 0001582313 · Large accelerated filer
Xenon Pharmaceuticals Inc.
Sign in to watch- Ticker
- XENE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- EIN
- 980661854
- Phone
- (604) 484-3300
- Business address
- 200 - 3650 GILMORE WAY, BURNABY, British Columbia, Canada
- Open-market buys, last 90 days
- $1,681,140
- in 2 filings
- Open-market sales, last 90 days
- $425,829
- in 1 filing, $426K under 10b5-1 plans
Net +$1,255,311. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-05-24 | MORTIMER IAN PRESIDENT & CEO | Option exercise · Stock Option (Right to Buy) | −42,592 | 0 | ||
| 2023-05-24 | MORTIMER IAN PRESIDENT & CEO | Option exercise · Stock Option (Right to Buy) | −20,576 | 0 | ||
| 2023-05-24 | MORTIMER IAN PRESIDENT & CEO | Option exercise · Stock Option (Right to Buy) | −6,172 | 0 | ||
| 2023-03-24 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Sale | −700 | $35.01 | $25K | 0 |
| 2023-03-10 | Von Seggern Christopher Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +90,000 | 90,000 | ||
| 2023-03-10 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2023-03-10 | DiFabio Andrea Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2023-03-10 | MORTIMER IAN PRESIDENT & CEO | Grant or award · Stock Option (Right to Buy) | +380,000 | 380,000 | ||
| 2023-03-10 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +120,000 | 120,000 | ||
| 2023-03-10 | EMPFIELD JAMES R. EVP, Drug Discovery | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2023-03-10 | AULIN SHERRY Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +120,000 | 120,000 | ||
| 2023-03-07 | PIMSTONE SIMON N. Director | Option exercise | +41,152 | $2.68 | $110K | 47,152 |
| 2023-03-07 | PIMSTONE SIMON N. Director | Shares withheld for taxes | −2,160 | $37.13 | $80K | 44,992 |
| 2023-03-07 | PIMSTONE SIMON N. Director | Sale | −10,990 | $37.01 | $407K | 34,002 |
| 2023-03-07 | PIMSTONE SIMON N. Director | Option exercise | +30,864 | $2.59 | $80K | 64,866 |
| 2023-03-07 | PIMSTONE SIMON N. Director | Shares withheld for taxes | −1,618 | $37.13 | $60K | 63,248 |
| 2023-03-07 | PIMSTONE SIMON N. Director | Sale | −8,242 | $36.94 | $304K | 55,006 |
| 2023-03-07 | PIMSTONE SIMON N. Director | Option exercise · Stock Option (Right to Buy) | −41,152 | 0 | ||
| 2023-03-07 | PIMSTONE SIMON N. Director | Option exercise · Stock Option (Right to Buy) | −30,864 | 0 | ||
| 2022-12-12 | AZAB MOHAMMAD Director | Option exercise | +3,086 | $2.68 | $8K | 69,905 |
Page 13 of 16 · 308 trades